%0 Journal Article
%T Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review
%A Hai-Hong Ran
%A Ran Zhang
%A Xue-Chun Lu
%A Bo Yang
%J 老年心脏病学杂志(英文版)
%D 2012
%I Science Press
%X Because it is safe and well tolerated, imatinib is a standard first-line therapy for chronic myeloid leukemia (CML). Although there have been sporadic reports of imatinib-induced cardiotoxicity, including left ventricle (LV) dysfunction and heart failure, the evidence for it is contradictory. Here, we reported a case of an 88-year-old male patient with CML developed decompensated heart failure following imatinib therapy. Four days after the initiation of imatinib, the patient developed orthopnea, edema and a pleural effusion accompanied by abdominal distension, nausea and vomiting. The chest X-ray film showed an enlarged cardiac profile. The echocardiogram demonstrated a decreased LV ejection fraction and enlarged left-side cardiac chambers. B-type natriuretic peptide concentrations were markedly increased. The patient recovered soon after the withdrawal of imatinib and introduction of comprehensive therapy for heart failure. Imatinib-induced cardiotoxicity in elderly patients is a potentially serious complication that merits further evaluation.
%K Heart failure
%K Chronic myeloid leukemia
%K Imatinib
%U http://www.jgc301.com/ch/reader/download_pdf.aspx?file_no=20120525001&year_id=2012&quarter_id=4&flag=1